FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC

Novel Cancer Vaccine Receives FDA Orphan Drug Designation in Cutaneous Melanoma

Videos
 

Reducing Secondary Diagnostic Delay Through the Breast Clinical Reporting and Data System Watch Now

Navigating the Surgical Nuances of Inflammatory Breast Cancer and Phyllodes Tumors   Watch Now

Trending

Adjuvant Chemo Noninferor at 3 Months Vs 6 Months in Stage II/III CRC   Read More

The Weight of Finances on Cancer Care: An Oncologist’s Perspective   Read More